Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
Infant
Female
Infant, Newborn
Humans
Child
United States
/ epidemiology
Infant, Premature
Respiratory Syncytial Virus Infections
/ epidemiology
Antiviral Agents
/ therapeutic use
Retrospective Studies
Hospitalization
Gestational Age
Respiratory Syncytial Virus, Human
Bronchiolitis
Palivizumab
/ therapeutic use
Journal
American journal of perinatology
ISSN: 1098-8785
Titre abrégé: Am J Perinatol
Pays: United States
ID NLM: 8405212
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
9
10
2023
pubmed:
28
10
2021
entrez:
27
10
2021
Statut:
ppublish
Résumé
In 2014, the American Academy of Pediatrics (AAP) changed its policy on the use of respiratory syncytial virus immunoprophylaxis (RSV-IP) so that RSV-IP was no longer recommended for use among infants without other medical conditions born >29 weeks of gestational age (wGA). This study examines 10-year trends in RSV-IP and RSV hospitalizations among term infants and preterm infants born at 29 to 34 wGA, including the 5 RSV seasons before and 5 RSV seasons after the AAP guidance change. A retrospective observational cohort study of a convenience sample of infants less than 6 months of age during RSV season (November-March) born between July 1, 2008, and June 30, 2019, who were born at 29 to 34 wGA (preterm) or >37 wGA (term) in the IBM MarketScan Commercial and Multi-State Medicaid databases. We excluded infants with medical conditions that would independently qualify them for RSV-IP. We identified RSV-IP utilization along with RSV and all-cause bronchiolitis hospitalizations during each RSV season. A difference-in-difference model was used to determine if there was a significant change in the relative rate of RSV hospitalizations following the 2014 policy change. There were 53,535 commercially insured and 85,099 Medicaid-insured qualifying preterm infants and 1,111,670 commercially insured and 1,492,943 Medicaid-insured qualifying term infants. Following the 2014 policy change, RSV-IP utilization decreased for all infants, while hospitalization rates tended to increase for preterm infants. Rate ratios comparing preterm to term infants also increased. The relative rate for RSV hospitalization for infants born at 29 to 34 wGA increased significantly for both commercially and Medicaid-insured infants (1.95, 95% CI: 1.67-2.27, We found that the previously identified increase in RSV hospitalization rates among infants born at 29 to 34 wGA persisted for at least 5 years following the policy change. · Immunoprophylaxis rates decreased after the 2014 American Academy of Pediatrics guidelines update.. · Rate of RSV hospitalization increased among preterm infants after the 2014 AAP guidelines update.. · Increase in RSV hospitalization persisted for at least 5 years after AAP guidelines update..
Identifiants
pubmed: 34704241
doi: 10.1055/s-0041-1736581
pmc: PMC10556298
doi:
Substances chimiques
Antiviral Agents
0
Palivizumab
DQ448MW7KS
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1529-1536Informations de copyright
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Déclaration de conflit d'intérêts
A.B. is currently employed by Moderna, Cambridge, MA, and was employed by Sobi at the time this study was conducted. T.G. is employed by Sobi. A.M.K. is currently employed by Aetion, New York, NY, and was employed by IBM Watson Health at the time this study was conducted. I.H.W., N.M.Z., and D.D. are employed by IBM Watson Health, which received funding from Sobi to conduct this study. L.R.K. has received research funding to their institution from Pfizer and Astra Zeneca, along with consultant fees from Pfizer and Sobi. J.F. has received grant/research support from AstraZeneca/MedImmune and is a member of the AstraZeneca and Sobi speaker's bureau. M.G. is employed at an institution that has received research funding from AstraZeneca.
Références
Eur J Pediatr. 2007 Dec;166(12):1267-72
pubmed: 17308898
Am J Perinatol. 2018 Jan;35(2):192-200
pubmed: 28881376
Ital J Pediatr. 2015 Dec 15;41:97
pubmed: 26670908
Am Fam Physician. 2011 Jan 15;83(2):141-6
pubmed: 21243988
J Infect Dis. 2022 Apr 1;225(7):1197-1204
pubmed: 32691037
Pediatrics. 1998 Sep;102(3):531-7
pubmed: 9724660
Pediatr Infect Dis J. 2002 Jul;21(7):629-32
pubmed: 12237593
Pediatrics. 2014 Aug;134(2):415-20
pubmed: 25070315
Hum Vaccin Immunother. 2021 May 4;17(5):1536-1545
pubmed: 33090914
Infect Dis Ther. 2018 Mar;7(1):87-120
pubmed: 29470837
Am J Perinatol. 2020 Jan;37(2):174-183
pubmed: 31430818
N Engl J Med. 2009 Feb 5;360(6):588-98
pubmed: 19196675
Pediatrics. 2013 Aug;132(2):e341-8
pubmed: 23878043
Pediatrics. 2009 Dec;124(6):1694-701
pubmed: 19736258
Am J Perinatol. 2018 Dec;35(14):1433-1442
pubmed: 29920638
MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):71-76
pubmed: 29346336
Pediatrics. 1998 Nov;102(5):1211-6
pubmed: 9794957
Infect Dis Ther. 2016 Dec;5(4):417-452
pubmed: 27628014
Matern Child Health J. 2016 Apr;20(4):808-18
pubmed: 26740227
J Pediatr. 2017 Feb;181:183-188.e1
pubmed: 27855996